Pharma & biotech

Former Novo Nordisk VP criticizes price of obesity drugs: "The only thing Novo Nordisk doesn't want to hear"

He believes that the industry should solve the problem of high prices leaving patients in the lurch instead of leaving it to politicians.
The price of obesity drugs like Wegovy should be set so that patients with the necessary medical need have access to it, according to a former top scientist at the company - just as the industry has worked to do with insulin. | Photo: Hollie Adams
The price of obesity drugs like Wegovy should be set so that patients with the necessary medical need have access to it, according to a former top scientist at the company - just as the industry has worked to do with insulin. | Photo: Hollie Adams
by ULRICH QUISTGAARD

Prominent American obesity researcher Richard DiMarchi is criticizing Novo Nordisk’s and Eli Lilly’s pricing of obesity drugs, which is cutting off many patients from possible treatment, Danish daily Berlingske writes.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
    • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading

    Jobs